PHILADELPHIA, Aug. 12, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced results for the period ended June 30, 2011. Echo's Quarterly Report on Form 10-Q is available through Echo's website at www.echotx.com.
Recent Corporate Highlights:In May 2011, Christopher P. Schnittker, CPA, joined Echo Therapeutics as its Chief Financial Officer. Mr. Schnittker is a senior executive with more than twenty years of financial management, reporting and corporate governance experience in the biotechnology and pharmaceutical industries. In May 2011, Echo's corporate headquarters relocated from Franklin, MA to Philadelphia, PA in response to Echo's growing and evolving business. Echo continues to expand its Franklin office as the operations hub for its engineering and product development personnel. Echo and its products have been featured in the press several times. Echo Therapeutics' needle-free Symphony tCGM System was featured in a story in the Philadelphia Inquirer on May 9, 2011 entitled " Former Surgeon Developing Needle-Free Technology." A podcast of MassDevice's interview w